Literature DB >> 15857351

Clinical experience in managing Fusarium solani keratitis.

H-C Lin1, P-H Chu, Y-H Kuo, S-C Shen.   

Abstract

Fusarium solani keratitis is a rare ocular infectious disease. The clinical characteristics and treatment methods of 18 patients with culture proven F. solani keratitis between July 1997 and December 2003 and with a follow-up period of more than 4 months were analysed retrospectively. The patients were divided into two groups based on the severity of keratitis. Group A (n = 13) displayed non-severe keratitis and were treated with debridement, lamellar keratectomy and antifungal medication. Group B (n = 5) displayed severe keratomycosis and were treated with lamellar keratectomy combined with amniotic membrane transplantation (AMT) and antifungal medication. In group A, wound healing did not interfere with the integrity of the anterior chamber. The mean re-epithelialisation time was 12.67 days (range: 5-21 days). All patients were free of major immediate postoperative complications. In group B, AMT preserved the anterior chamber integrity in two cases, but failed to do so in the other three cases. Therapeutic patch grafts were required in these three cases. Non-severe F. solani keratitis is best treated with superficial keratectomy. Timely AMT combined with lamellar keratectomy appears to be an adjuvant therapy for severe keratomycosis and avoiding emergent therapeutic penetrating keratoplasty. However, AMT was effective in cases involving non-suppurative Fusarium keratitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857351     DOI: 10.1111/j.1368-5031.2005.00399.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  9 in total

1.  Antifungal efficacy of voriconazole, itraconazole and amphotericin b in experimental fusarium solani keratitis.

Authors:  Güliz Fatma Yavas; Faruk Oztürk; Tuncay Küsbeci; Zafer Cetinkaya; Sitki Samet Ermis; Nuri Kiraz; Umit Ubeyt Inan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-02       Impact factor: 3.117

Review 2.  Case Report: Corneal Coinfection with Fungus and Amoeba: Report of Two Patients and Literature Review.

Authors:  Joveeta Joseph; Sunita Chaurasia; Savitri Sharma
Journal:  Am J Trop Med Hyg       Date:  2018-07-12       Impact factor: 2.345

3.  Comparison of modified corneal cross-linking with intrastromal voriconazole for the treatment of fungal corneal ulcer.

Authors:  Yingxin Chen; Xingya Miao; Minghong Gao; Lixin Song
Journal:  Exp Ther Med       Date:  2021-05-21       Impact factor: 2.447

4.  Early keratectomy in the treatment of moderate Fusarium keratitis.

Authors:  Hsin-Chiung Lin; Ja-Liang Lin; Dan-Tzu Lin-Tan; Hui-Kang Ma; Hung-Chi Chen
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

5.  A Combination of Intrastromal and Intracameral Injections of Amphotericin B in the Treatment of Severe Fungal Keratitis.

Authors:  Jianzhang Hu; Jingjin Zhang; Yanling Li; Xiaoli Han; Weidong Zheng; Juan Yang; Guoxing Xu
Journal:  J Ophthalmol       Date:  2016-09-19       Impact factor: 1.909

6.  Keratomycosis in captive red pandas (Ailurus fulgens): 2 cases.

Authors:  Hayley August Volk; Anu O'Reilly; Kate Bodley; Helen McCracken
Journal:  Open Vet J       Date:  2018-06-01

7.  Update on the treatment of disseminated fusariosis: Focus on voriconazole.

Authors:  Marta Stanzani; Fabio Tumietto; Nicola Vianelli; Michele Baccarani
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

8.  Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis.

Authors:  Masanori Niki; Hiroshi Eguchi; Yuki Hayashi; Tatsuro Miyamoto; Fumika Hotta; Yoshinori Mitamura
Journal:  Clin Ophthalmol       Date:  2014-06-05

9.  Therapeutic Effect of Intrastromal Voriconazole, Topical Voriconazole, and Topical Natamycin on Fusarium Keratitis in Rabbit.

Authors:  Mahmood Nejabat; Nafiseh Yaqubi; Amir Khosravi; Kamiar Zomorodian; Mohammad Javad Ashraf; Ramin Salouti
Journal:  J Ophthalmol       Date:  2016-05-19       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.